The diagnosis and prognosis of mi are of paramount importance in addressing this critical health issue. timely and accurate detection is crucial to ensure that appropriate interventions can be initiated promptly, potentially saving lives and minimizing long-term complications. however, the current diagnostic landscape faces several challenges, hindering effective management and treatment of mi. one of the primary challenges in mi diagnosis is the dependency on highly skilled healthcare professionals and complex diagnostic procedures. traditional diagnostic methods often require extensive laboratory infrastructure, sophisticated equipment, and trained analysts. enzyme-linked immunosorbent assay (elisa) and spectrophotometry methods are commonly employed but necessitate specialized laboratories and time-consuming processes. this reliance on centralized diagnostic facilities can lead to delays in obtaining critical diagnostic information, especially in remote or underserved regions, ultimately impacting patient outcomes. moreover, the symptoms of mi can be subtle or easily mistaken for other conditions, making early diagnosis even more challenging. patients often experience chest pain, shortness of breath, and fatigue, but these symptoms can be attributed to various other ailments, leading to misdiagnosis or delayed intervention. such delays can exacerbate the severity of the heart attack, increase the risk of complications, and reduce the chances of a full recovery. in addition to these challenges, the economic burden of mi on healthcare systems and individuals is substantial. the costs associated with hospitalization, diagnostic tests, surgical procedures, and post-operative care can be overwhelming. furthermore, the prolonged recovery periods and potential long-term disabilities can lead to a significant reduction in the quality of life for mi survivors. to address these critical issues surrounding mi diagnosis and prognosis, the proposed cardiac screening device represents a groundbreaking solution. by incorporating a combination of biomarkers and electrocardiography (ecg) technology, this device offers a paradigm shift in the way mi is detected and managed. designed for home-based use, the device empowers individuals to take control of their heart health, enabling regular monitoring and early detection of any potential cardiac issues. the integration of multiple biomarkers and ecg signals ensures a comprehensive analysis of heart health, allowing for a more accurate and timely diagnosis of mi. this is a game-changer, especially for individuals who may not have easy access to healthcare facilities or for those who require continuous monitoring due to pre-existing cardiac conditions. the user-friendly design of the device ensures that it can be operated with ease by individuals of varying age groups and backgrounds. furthermore, the real-time data transmission capability of the device to healthcare providers is a crucial feature. it facilitates a more efficient and effective response to any changes in the patient's health status. healthcare professionals can remotely monitor patients, offer timely interventions, and make informed decisions, ultimately improving patient outcomes. in conclusion, the proposed cardiac screening device holds the promise to revolutionize the diagnosis and prognosis of myocardial infarction (mi), a global health challenge of immense proportions. by integrating biomarkers and ecg technology into a user-friendly and convenient home-based device, it addresses the major bottlenecks in mi diagnosis. this innovation not only has the potential to save lives by enabling early and accurate detection but also reduces the burden on healthcare systems and offers a cost-effective solution for monitoring heart health. it represents a significant opportunity to enhance the lives of mi patients worldwide and mitigate the global impact of this devastating cardiac disorder.